Company Encyclopedia
View More
name
JSSH
000518.SZ
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusen, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass; Xinde Lusheng; Xin Lisheng; and Ring BO. It also engages in breeding and sales of flowers and seedlings; and landscaping projects.
1.579 T
000518.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking59/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-26.16%E
    • Profit Margin-31.61%E
    • Gross Margin33.58%C
  • Growth ScoreB
    • Revenue YoY61.67%A
    • Net Profit YoY-132.07%E
    • Total Assets YoY-21.62%E
    • Net Assets YoY-22.48%E
  • Cash ScoreC
    • Cash Flow Margin-316.35%D
    • OCF YoY61.67%A
  • Operating ScoreB
    • Turnover0.59B
  • Debt ScoreB
    • Gearing Ratio24.29%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sihuan Bio released its first-quarter performance, with a net loss attributable to the parent company of 15.9147 million yuan

    According to the Zhitong Finance APP, JSSH released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 43.8417 million yuan, a year-on-year decrease of 22.26%. The net loss attributable to shareholders of the listed company was 15.9147 million yuan. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 18.566 million yuan

    Zhitong·
    SZ
    000518
    +1.60%
    Zhitong·
    SZ
    000518
    +1.60%

    JSSH: Subsidiary removed from the list of dishonest executors

    On the evening of April 17th, JSSH announced that its wholly-owned subsidiary, Chenwei Ecological Park, has paid the relevant outstanding amounts. According to the information displayed on the China Execution Information Disclosure Network, Chenwei Ecological Park has been removed from the list of dishonest executors

    Zhitong·
    SZ
    000518
    +1.60%
    Zhitong·
    SZ
    000518
    +1.60%

    JSSH: It is expected that the net profit for the fiscal year 2024 will be negative and revenue will be below 300 million, and the stock may be subject to delisting risk warning

    JSSH announced that, according to preliminary calculations by the finance department, the audited net profit for the year 2024 is expected to be negative and the operating income after deductions will be less than 300 million yuan, which will trigger the delisting risk warning conditions stipulated in Article 9.3.1 of the Shenzhen Stock Exchange Listing Rules. The company's stock may be subject to delisting risk warnings after the disclosure of the 2024 annual report

    Zhitong·
    SZ
    000518
    +1.60%
    Zhitong·
    SZ
    000518
    +1.60%

    JSSH "Girl's Needle" approved, becoming the third in China

    On April 1st, the National Medical Products Administration's medical device approval document delivery information showed that JSSH's subsidiary, Meiyan Space Biotechnology Co., Ltd., has received approval for its injectable polycaprolactone microsphere facial filler. This is the third approved "youth needle" in the country. Previously, only two similar products had been approved domestically, namely Yiyanshi from Huadong Medicine and Su Yan Zhen·Zhen Yu from Shandong Caicai Medical Technology Co., Ltd

    Zhitong·
    SZ
    000518
    +1.60%
    Zhitong·
    SZ
    000518
    +1.60%

    Performance expected to be a loss, this company faces delisting risk! | Selected After-Hours Announcements

    JSSH expects a net profit loss for the fiscal year 2024 and faces a risk warning for delisting. DZH plans to sell its wholly-owned subsidiary for 35.305 million yuan to optimize its asset structure. HUAMING plans to repurchase 150 million to 200 million yuan worth of shares for an employee stock ownership plan. ZTE intends to use no more than 30 billion yuan of its own funds for entrusted wealth management and expects a net profit of 8.425 billion yuan in 2024, a year-on-year decrease of 9.66%

    JIN10·
    SZ
    000518
    +1.60%
    SZ
    002270
    +3.38%
    SH
    601519
    +6.85%
    JIN10·
    SZ
    000518
    +1.60%
    SZ
    002270
    +3.38%
    SH
    601519
    +6.85%
    © 2025 Longbridge｜Disclaimer